Ophthalmological side effects of antidepressant, anxiolytic and mood stabilizer agents;Effetti oftalmologici indesiderati dei farmaci antidepressivi, ansiolitici e stabilizzatori del tono dell'umore

Minerva Psichiatrica

Volumn 46, Issue 4, 2005, Pages 301-313

  Fornaro, P ^a   Venuti, S ^a   Fornaro, M ^a   Sartore, F ^a   Gabrielli, F ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Anticon vulsants; Antidepressants; Anxiolytics; Lithium; Ophthalmological side effects

Indexed keywords

AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BETHANECHOL; BROFAROMINE; CARBAMAZEPINE; CITALOPRAM; CLOMIPRAMINE; CLORGYLINE; DESIPRAMINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; ISOCARBOXAZID; LITHIUM; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; MOOD STABILIZER; OXCARBAZEPINE; PAROXETINE; PHENELZINE; PHENOTHIAZINE DERIVATIVE; SERTRALINE; TOPIRAMATE; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIFLUOPERAZINE; TRIMIPRAMINE;

ACCOMMODATION PARALYSIS; BIPOLAR DISORDER; BLINDNESS; CLOSED ANGLE GLAUCOMA; DRUG MECHANISM; EXTRAPYRAMIDAL SYMPTOM; EYE DISEASE; EYE INJURY; HEALTH HAZARD; HUMAN; LONG TERM CARE; MYDRIASIS; NEUROTOXICITY; PATIENT COMPLIANCE; PATIENT MONITORING; REVIEW; WEIGHT REDUCTION;

EID: 32244433344     PISSN: 03749320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (99)

1. Fraunfelder FT. Drug-Induced Ocular Side Effects and Drug Interactions. Philadelphia: Lea & Febiger; 1976.
2. Oshika T. Ocular adverse effects of neuropsychiatric agents. Incidence and management. Drug Saf 1995;12: 256-63.
3. Malone DA Jr, Camara EG, Krug JH. Ophthalmological effects of psychotropic medications. Psychosomatics 1992;33:271-7.
4. Lieberman E, Stoudemire A. Use of tricyclic antidepressants in patients with glaucoma: assessment and appropriate precautions. Psychosomatics 1987;28:145-8.
5. Shur E, Checkley S. Pupil studies in depressed patients: an investigation of the mechanism of action of desipramine. Br J Psychiatry 1982;140:181-4.
6. Lowe RF, Ritch R. Angle-closure glaucoma. Clinical types. In: Ritch R, Schields MB, Krupin T, editors. The glaucoma's. St. Louis: CY Mosby; 1989.p.839-53.
7. Goode DJ. Increased palpebral aperture in a patient receiving amitriptyline. Am J Psychiatry 1977;134:1043-4.
8. Armitage R, Trivedi M, Rush AJ. Fluoxetine and oculomotor activity during sleep in depressed patients. Neuropsychopharmacology 1995;12:159-65.
9. Karson CN. Spontaneous eye-blink rates and dopaminergic system. Brain 1983;106 (Pt 3):643-53.
10. Damsa C, Bumb A, Bianchi-Demicheli F, Vidailheit P, Sterck R, Andreoli A et al. Dopamine-dependent side effects of selective serotonin reuptake inhibitors: a clinical review. J Clin Psychiatry 2004;8:1064-8.
11. Gorman M, Barkley GL. Oculogyric crisis induced by carbamazepine. Epilepsia 1995;11:1158-60.
12. Gatzonis SD, Georgaculias N, Singounas E, Jenkins A, Stamboulis E, Siafakas A. Elimination of oxcarbazepine-induced oculogyric crisis following vagus nerve stimulation. Neurology 1999;52:1918-9.
13. Colasanti BK, Trotter RR. Effects of selective inhibition of type A and type B monoaminooxydase on intraocular pressure in the cat and the rabbit. Curr Eye Res 1981-1982;1:501-6.
14. Bitsios P, Langley RW, Tavernor S, Pyykko K, Scheinin M, Szabad Bradshaw CM. Comparison of the effects of Moclobemide and Selegiline on Tyramine-evoked mydriasis in man. Br J Pharmacol 1998;6:551-8.
15. Fornaro P, Calabria G, Corallo G, Picotti GB. Pathogenesis of degenerative retinopathies induced by thioridazine and other antipsychotics: a dopamine hypothesis. Doc Ophthalmol 2002;105:41-9.
16. De Feo G, Piccinelli D, Putzolo S, Silvestrini B. Effects of topically instilled drugs on intraocular pressure in rabbits. Artzneimittelforschung 1975;5:806-9.
17. Hughes MS, Lessell S. Trazodone-induced palinopsia. Arch Ophthalmol 1990;108:399-400.
18. Kraus R. Visual trails with Nefazodone treatment. Am J Psychiatry 1996;153:1365-6.
19. Horton JC, Trobe JD. Akinetopsia from Nefazodone toxicity. Am J Ophthalmol 1999;128:530-1.
20. Schwanz K. Nefazodone and visual side effects. Am J Psychiatry 1997;184:1038.
21. Greenberg WM. Visual field shimmering associated with Nefazodone. J Clin Psychiatry 1999;60:124.
22. Mosberian P, Leung M, Hollander Y, Remick RA. Nefazodone - induced visual disturbances. Can J Psychiatry 1999;44:925-6.
23. Levi L, Miller NR. Visual illusions associated with previous drug abuse. J Clin Neurophthalmol 1990;10:103-10.
24. Kawasaki A, Purvin V. Persistent palinopsia following ingestion of lysergic acid diethylamide (LSD). Arch Ophthalmol 1996;114:47-50.
25. Aldurra G, Crayton JW. Improvement of hallucinogen persisting disorder by treatment with a combination of fluoxetine and olanzapine: a case report. J Clin Psychopharmacol 2001;16:343-4.
26. Young CR. Sertraline treatment of hallucinogen persisting perception disorder. J Clin Psychiatry 1997;58:85.
27. Lerner AG, Finkel B, Oyffe I, Merenzon I, Sigal M. Clonidine treatment of hallucinogen persisting perception disorder. Am J Psychiatry 1998;155:1460.
28. Abraham HD, Mamen A. LSD-like panic from risperidone in post-LSD visual disorder. J Clin Psychopharmacol 1996;16:238-41.
29. Luu C, Kiely P, Crewther A, Kowal L, Crewther S. Central and peripheral vision loss associated with nefazodone usage. Doc Ophthalmol 2003;106: 319-25.
30. Barrett J. Anisocoria associated with selective serotonin reuptake inhibitors. BMJ 1994;309:1620.
31. Larson M, Holstein S. Selective serotonin reuptake inhibitor-induced mydriasis. J Am Acad Child Adolesc Psychiatry 2000;39:138-9.
32. Schreiber S, Pick CG. Fluoxetine for blepharospasm: interaction of serotonin and dopamine. Clin Sci 1995;89: 591-9.
33. Browning AC, Reck AC, Chisholm IH, Nishal KK. Acute angle closure glaucoma presenting in a young patient after administration of paroxetine. Ophthalmologica 2000;214:360-1.
34. Bennett HG, Wyllie AM. Paroxetine and acute angle-closure glaucoma. J Am Acad Child Adolesc Psychiatry 2000;39:138-9.
35. Strickland GM, Hough DW. Unilateral facial numbness and visual blurring associated with paroxetine discontinuation. Eye 1999;13 (Pt 5):691-2.
36. Jimenez-Jimenez FJ, Orti-Paneja M, Zurdo JM. Aggravation of glaucoma with fluvoxamine. Ann Pharmacother 2001;12:1565-6.
37. Sener EC, Kiratli H. Presumed sertraline maculopathy. Acta Ophthalmol Scand 2001;79:428-30.
38. Oca MG, Donn SM. Association of maternal sertraline (Zoloft) therapy and transient neonatal nystagmus. J Perinatol 1999;19:460-1.
39. Lehman NL, Johnson LN. Toxic optic neuropathy after a concomitant use of melatonin, zoloft, and a high-protein diet. J Neuroophthalmol 1999;19:232-4.
40. Rojas VM, Silva R. Palpebral twitching in a depressed adolescent on citalopram. J Child Adolesc Psychopharmacol 2001;11:295-9.
41. Aragona M, Inghilleri M. Increased ocular pressure in two patiens with narrow angle glaucoma treated with venlafaxine. Clin Neuropharmacol 1998;21:130-1.
42. Lutz EG. Allergic conjunctivitis due to diazepam. Am J Psychiatry 1975;132:548.
43. Hyams SW, Keroub C. Glaucoma due to diazepam. Am J Psychiatry 1977;134:447-8.
44. Ong BY, Pickering BG, Pulanhiuk BK, Cumming M. Lorazepam and diazepam as adjustments to epidural anaesthesia for caesarian section. Can J Anesth 1982;29:31-4.
45. Arai M, Fujii S. Divergence paralysis associated with the ingestion of diazepam. J Neurol 1990;237:45-6.
46. Kadoi C, Hayasaka S, Tsukamoto E, Matsumoto M, Hayasaka Y, Nagaki Y. Bilateral angle closure glaucoma and visual loss precipitated by antidepressant and antianxiety agents in a patient with depression. Ophthalmologica 2000;214:360-1.
47. Speeg-Schatz C, Giersch A, Boucart M, Gottenkiene S, Tondre M, Kauffmann-Muller F et al. Effects of lorazepam on vision and oculomotor balance. Binocul Vis Strabismus 2001;16:99-104.
48. Giersch A, Boucart M, Speeg-Schatz C, Muller-Kauffmann F, Danion JM. Lorazepam impairs perceptual integration of visual forms: a central effect. Psychopharmacology 1996;126:260-70.
49. Maillet J, Perier JF, Girard P, Maillet, Forest A, Deligne P. [Effects of flunitrazepam on intraocular pressure]. J Fr Ophthalmol 1982;5:335-338.
50. Horiguchi J, Inami Y. Effect of clonazepam on neuroleptic-induced oculogyric crisis. Acta Psychiatr Scand 1989;5:521-3.
51. Carlow TJ. Medical treatment of nystagmus and ocular motor disorders. Int Ophthalmol Clin 1986;4:251-64.
52. Averhuch-Heller L. Acquired nystagmus. Curr Treat Options Neurol 1999;1:68-73.
53. Gatzonis S, Karadimas P, Gatzonis S, Bouzas EA. Clonazepam associated retinopathy. Eur J Ophthalmol 2003;13:813-5.
54. Stapleton JM, Guthrie S, Linnoila M. Effects of alcohol and other psychotropic drugs on eye movements: relevance to traffic safety. J Stud Alcohol 1986;47: 426-32.
55. Fornaro P, Giberti F, Albano C, Cultrera S, Lunardi G. Lamotrigine in the treatment of major depression. Preliminary results from an open study on outpatients. It J Psychiatry Behav Sci 1997;3:114-8.
56. Bourgeois JA. Ocular side effects of lithium - a review. J Am Optom Assoc 1991;7:548-51.
57. Lee MS, Lessell S. Lithium-induced periodic nystagmus. Neurology 2003;2:344.
58. Corbett JJ, Jacobson DM, Thompson HS, Hart MN, Albert DW. Downbeating nystagmus and other ocular motor defects caused by lithium toxicity. Neurology 1989;4:481-7.
59. Caplan RP, Fry MM. Photophobia in lithium intoxication. Br Med J 1982;285:1314-5.
60. Schmidt-Betschel W, Aust W. [Effect of long-term lithium therapy on the pigment epithelium and optic nerve] Ophthalmologic 1994;91:198-200.
61. Halmagyi GM, Rudge P, Gresty MA, Sanders MD. Downbeat nystagmus - a review of 62 cases. Arch Neurol 1983;13:777-84.
62. Sandyk R. Oculogyric crisis induced by lithium carbonate. Eur Neurol 1984;23:92-4.
63. Pakes GE. Eye irritation and lithium carbonate. Arch Ophthalmol 1980;98:930.
64. Byrne AP, Delaney WJ. Regression of thyrotoxic ophthalmopathy following lithium withdrawal. Can J Psychiatry 1993;38:635-7.
65. Lobo A, Pilek E, Stokes PE. Papilledema following therapeutic dosages of lithium carbonate. J Nerv Ment Dis 1978;166:526-9.
66. Seggie J, Werstiuk ES, Grota L. Lithium and circadian patterns of melatonin in the retina, hypothalamus, pineal and serum. Prog Neuropsychopharmacol Biol Psychiatry 1987;11:325-34.
67. Seggie J. Lithium and retina. Prog Neuropsychopharmacol Biol Psychiatry 1988;12:241-53.
68. Seggie J, Carney PA, Parker J, Grof E, Grof P. Effect of chronic lithium on sensitivity to light in male and female bipolar patients. Prog Neuropsychopharmacol Biol Psychiatry 1989;13:543-9.
69. Wirz-Justice A, Remé C, Prünte A, Heinen U, Graw P, Urner U. Lithium decrease retinal sensitivity, but this is not cumulative with years of treatment. Biol Psychiatry 1997;41:743-6.
70. Emrich HM, Zihl J, Raptis C, Wendl A. Reduced dark-adaptation: an indication of lithium's neuronal action in humans. Am J Psychiatry 1990;147:629-31.
71. Federspiel-Eisenring E, Reme C, Pfeilschifter J, Dietrich C. Lithium-induced lesions in the rat retina-potentiation by light. Klin Monatsbl Augenheilkd 1988;192:134-40.
72. Huang X, Wu DY, Chen G, Manji H, Chen DF. Support of retinal ganglion cell survival and axon regeneration by lithium through a Bcl-2-dependent mechanism. Invest Ophthalmol Vis Sci 2003;44:347-54.
73. Reichenbach A, Pritz-Hohmeier S, Michel H, Malz CR, Meyer DL. LiCl-induced malformations of the eyes and the rostral CNS in Xenopus laevis. J Hirnforsch 1997;38:35-45.
74. Chrousos GA, Cowdry R, Schuelein M, Abdul-Rahim AS, Matsuo V, Currie JN. Two cases of downbeat nystagmus and oscillopsia associated with carbamazepine. Am J Ophthalmol 1987;103:221-4.
75. Schwartzman MT, Leppik IE. Carbamazepine-induced dyskinesia and ophthalmologia. Clev Clin J Med 1990;4:367-72.
76. Bayer A, Thiel HJ, Zrenner E, Paulus W, Ried S, Schmidt D. Disorders of colour perception and increase sensitivity in phenytoine and carbamazepine therapy. Ocular side effects of anticonvulsants. Nerverartz 1995;2:89-96.
77. Lopez L, Thompson A, Rabinowicz AL. Assessment of colour vision in epileptic patients exposed to single-drug therapy. Eur Neurol 1999;4:201-5.
78. Hilton EJ, Hosking SL, Betts T. The effect of antiepileptic drugs on visual performace. Seizure 2004;2:113-28.
79. Nielsen NV, Syversen K. Possible retinotoxic effect of carbamazepine. Acta Ophthalmol 1986;64:287-90.
80. Yee RD, Purvin VA, Azzarelli B, Nelson PB. Intermittent dyplopia and strabismus caused by ocular neuromotormyotomia. Trans Ophthalmol Soc 1996;94:207-23.
81. Ezra E, Spalton D, Sanders MD, Graham EM, Plant GT. Ocular neuromyotonia. Br J Ophthalmol 1996;4: 350-5.
82. Sutcliffe AG, Jones RB, Woodruff G. Eye malformations associated with treatment with carbamazepine during pregnancy. Ophthalmic Genet 1998;2:59-62.
83. Goto Y, Taniwaki T, Shigematsu J, Tobimatsu S. The long-term effects of antiepilectic drugs on the visual system of rats: electrophysiological and histopathological studies. Clin Neurophysiol 2003;8:1395-402.
84. Harding GF, Alford CA, Powell TE. The effect of sodium valproate on sleep, reaction times, and visual evoked potential in normal subjects. Epilepsia 1985;26: 597-601.
85. Gigantelli JW, Braddock SR, Johnson LN. Blepharoptosis and central nervous system abnormalities in combined valproate and hydantoin embriopathy. Plast Reconstr Surg 2000;1:52-4.
86. Mc Mahon CL, Braddock SR. Septo-optic dysplasia as a manifestation of valproic acid embriopathy. Teratology 2001;2:83-6.
87. Nemet A, Nesher R, Almog Y, Assia E. Bilateral acute angle-closure glaucoma following topiramate treatment. Harefush 2002;7:597-99.
88. Banta JT, Hoffman K, Budenz DL, Ceballos E, Greenfeld DS. Presumed topiramate-induced bilateral angle-closure glaucoma. Am J Ophthalmol 2001;1:112-4.
89. Sills GJ, Butler E, Forrest G, Ratnaraj N, Patsalos PN, Brodie MJ. Vigabatrin, but not gabapentin or topiramate, produces concentration-related effects on enzymes and intermediates of the GABA shunt in rat brain and retina. Epilepsia 2003;44:886-92.
90. Craig JE, Ong TJ, Lamis DL, Wells JM. Mechanism of topiramate-induced acute-onset myopia and angle closure glaucoma. Am J Ophthalmol 2004;1:193-5.
91. Fraunfelder FW, Fraunfelder FT, Keates EU. Topiramate associated acute, bilateral, secondary angle-closure glaucoma. Ophthalmology 2004;111:109-11.
92. Yoneda S, Tanaka E, Goto W, Ota T, Hara H. Topiramate reduces excitotoxic and ischemic injury of rat retina. Brain Res 2003;967:257-66.
93. Steinhoff BJ, Freudenthaler N, Paulus W. The influence of established and new antiepileptic drugs on visual perception. A placebo-controlled, double-blind, single-dose study in healthy volunteers. Epilepsy Res 1997;1:35-47.
94. Das KB, Harris C, Smyth DP, Cross JH. Unusual side effects of lamotrigine therapy. J Child Neurol 2003;7: 479-80.
95. Pisani F, Pedale S, Macairone V, Torre, Oteri G, Avanzini G et al. Neuroprotective effects of lamotrigine and remacemide on exitotoxicity induced by glutamate agonists in isolated chick retina. Exp Neurol 2001;1:102-70.
96. Reeves AL, So EL, Sharbrough FW, Krahn LE. Movement disorders associated with the use of gabapentin. Epilepsia 1996;37:988-90.
97. Stahl JS, Rottach KG, Averbuch-Heller L, von Maydell RD, Collins SD, Leigh RJ. A pilot study of gabapentin as treatment for acquired nystagmus. Neuro-ophthalmology 1996;16:107-13.
98. Tusa RJ. Nystagmus: diagnostic and therapeutic strategies. Semin Ophthalmol 1999;14:65-73.
99. Jehle T, Lagreze WA, Blauth E, Knorle R, Schnierle P, Lucking CE et al. Gabapentin-lactam (8-aza-spiro[5,4] decan-9-on; GBP-L) inhibits oxygen glucose deprivation-induced [3H] glutmate release and is a neuroprotective agent in a model of acute retinal ischemia. Naunyn Schmiedebergs Arch Pharmacol 2000;74-81.